Please sign in to follow a disease.
Liquidia Technologies, Inc.
Clinical trials sponsored by Liquidia Technologies, Inc., explained in plain language.
Biopharmaceutical company developing inhaled therapies for pulmonary diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can an inhaled powder calm the painful Cold-Finger attacks of scleroderma? Results expected Feb 2027 (estimated)
- Can an inhaled therapy replace a daily pill for PAH? Results expected May 2027 (estimated)
- New inhaled powder for lung blood pressure condition tested in 80 patients Results expected Jul 2027 (estimated)